Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company pioneering AAV-based therapies for severe genetic disorders of the central nervous system. This page aggregates official news and press releases related to TSHA's innovative pipeline, regulatory progress, and strategic initiatives.
Investors and industry professionals will find timely updates on clinical trial developments, including TSHA-102 for Rett syndrome, regulatory designations like RMAT status, and research collaborations advancing gene therapy science. The curated collection serves as a centralized resource for tracking milestones in TSHA's mission to address unmet needs in monogenic CNS diseases.
Content spans multiple categories including therapy development updates, manufacturing advancements, partnership announcements with academic institutions, and financial disclosures. All materials maintain factual reporting on completed events without speculative commentary.
Bookmark this page for streamlined access to verified information about TSHA's progress in developing transformative genetic medicines. Check regularly for new developments in their clinical programs and scientific innovations.
Taysha Gene Therapies (Nasdaq: TSHA) has initiated screening for its Phase 1/2 REVEAL trial targeting Rett syndrome, with the first adult patient anticipated to be dosed in H1 2023. The company plans to submit a Clinical Trial Application to the UK MHRA and an IND to the U.S. FDA for TSHA-102 in pediatric patients in mid-2023 and H2 2023, respectively. Taysha's research and development expenses decreased significantly to $13.9 million in Q4 2022 from $37.9 million a year prior. Despite a net loss of $55.7 million for Q4 2022, the company holds $87.9 million in cash, expected to cover expenses into Q1 2024.
Taysha Gene Therapies (Nasdaq: TSHA) will disclose its financial results for Q4 and full-year 2022 on March 28, 2023, at 4:30 PM ET.
The conference call will provide updates on the company's progress in developing AAV-based gene therapies for rare CNS diseases. Participants can join via toll-free and international numbers. Taysha aims to eradicate monogenic CNS diseases by leveraging expertise and a robust gene therapy program.
Taysha Gene Therapies (Nasdaq: TSHA) provided an update on its TSHA-120 program for giant axonal neuropathy (GAN) following a Type B end-of-Phase 2 meeting with the FDA. The FDA acknowledged MFM32 as an acceptable endpoint and recommended dosing additional patients to support a Biologics License Application (BLA) submission. The company also announced the anticipated dosing of the first adult patient with Rett syndrome and plans to submit a Clinical Trial Application (CTA) in mid-2023. New management has implemented operational changes to enhance execution and milestones in 2023 are expected to drive key clinical developments.
Taysha Gene Therapies (Nasdaq: TSHA) has announced significant executive leadership changes as of December 16, 2022. Sean P. Nolan, formerly Chair of the Board, is now the Chief Executive Officer, succeeding RA Session II, who remains on the Board. Dr. Sukumar Nagendran has been appointed President and Head of R&D. Both leaders aim to advance clinical programs in Giant Axonal Neuropathy (GAN) and Rett syndrome and strengthen Taysha's partnership with Astellas. The company plans to host an investor call in January to discuss feedback from the FDA regarding GAN.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
